Dr. Bert Bravenboer, inwendige geneeskunde
0565.978.271 · rovalta.com · 27/09/2026
NORMAL SITUATION
Dr. Bert Bravenboer, inwendige geneeskunde
Company — Normal situation.
Financial year 2024 · Closed on 31/12/2024
Net result12,4 k €+214,0 %over 1 year
Gross margin6,1 k €-40,8 %over 1 year
Equity436,8 k €+2,9 %over 1 year
Workforce0,0 ETP
Overview
Identity
Source · BCE/KBODr. Bert Bravenboer, inwendige geneeskunde is a company registered in Belgium.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0565.978.271
- Legal form
- Private company with limited liability
- Contributed capital
- 18 600,00 €
- Latest accounts
- 31/12/2024
- Average workforce
- 0,0 ETP
Signals
ProfitableSolid equityGood liquidityPositive cashflowPositive EBITDA
Financials
Source · NBB, 9 filingsTrend over 9 financial years
| 2024 | 2023 | 2022 | 2021 | 2020 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 6,1 k € | -40.8% | 10,2 k € | -42.9% | 17,9 k € | -76.7% | 76,7 k € | +31.2% | 58,5 k € |
| EBITDA | 5,5 k € | -38.7% | 9,1 k € | -49.1% | 17,8 k € | -76.3% | 75,2 k € | +31.5% | 57,2 k € |
| Operating result | 5,5 k € | +436% | -1,7 k € | -114% | 11,9 k € | -84.0% | 74,6 k € | +31.5% | 56,8 k € |
| Net result | 12,4 k € | +214% | 4 k € | -70.8% | 13,6 k € | -79.2% | 65,3 k € | +24.9% | 52,3 k € |
| Balance sheet | |||||||||
| Equity | 436,8 k € | +2.9% | 424,4 k € | +0.9% | 420,4 k € | +3.3% | 406,8 k € | +19.1% | 341,6 k € |
| Total assets | 452,2 k € | +4.5% | 432,7 k € | +1.2% | 427,4 k € | +2.7% | 416,2 k € | +20.7% | 344,8 k € |
| Cash | 74 k € | -35.1% | 114,1 k € | +6.0% | 107,6 k € | -16.7% | 129,2 k € | +53.2% | 84,3 k € |
| Debts | 7,8 k € | -6.8% | 8,4 k € | +19.1% | 7 k € | -24.8% | 9,3 k € | +191% | 3,2 k € |
| Other | |||||||||
| Workforce | 0,0 ETP | – | – | – | – | ||||
Board of directors
Source · NBB, accounts to 31/12/20241 active · 4 ended
Active mandates
Bert Bravenboer
ActiveEnded mandates
B. Bravenboer
EndedB. Bravenboer
EndedB. Bravenboer
EndedBert Bravenboer
EndedFinancials
Full financial information
Source · NBB| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 | 01/01/2019 |
| Closing of the financial year | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 | 31/12/2019 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 09/05/2025 | 29/08/2024 | 21/08/2023 | 26/08/2022 | 23/08/2021 | 08/10/2020 |
| General meeting | 28/02/2025 | 04/06/2024 | 06/06/2023 | 30/06/2022 | 30/06/2021 | 08/09/2020 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for freeAnnual accounts filings
Source · NBB, 9 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 31/12/2024 | 28/02/2025 | 09/05/2025 | Dutch | |
| Abridged model | 31/12/2023 | 04/06/2024 | 29/08/2024 | Dutch | |
| Abridged model | 31/12/2022 | 06/06/2023 | 21/08/2023 | Dutch | |
| Abridged model | 31/12/2021 | 30/06/2022 | 26/08/2022 | Dutch | |
| Abridged model | 31/12/2020 | 30/06/2021 | 23/08/2021 | Dutch | |
| Abridged model | 31/12/2019 | 08/09/2020 | 08/10/2020 | Dutch | |
| Abridged model | 31/12/2018 | 04/06/2019 | 30/09/2019 | Dutch | |
| Abridged model | 31/12/2017 | 30/06/2018 | 28/09/2018 | Dutch | |
| Abridged model | 31/12/2015 | 05/10/2016 | 17/10/2016 | Dutch |
Valuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 31/12/20241 active · 4 ended
Active mandates
Bert Bravenboer
ActiveEnded mandates
B. Bravenboer
EndedB. Bravenboer
EndedB. Bravenboer
EndedBert Bravenboer
EndedOwnership and network
Looking for more information about this company?
Try for freePublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Dissolution29/04/2025RUBRIEK EINDE (STOPZETTING, INTREKKING STOPZETTING, NIETIGHEID, GER. AK., GERECHTELIJKE REORGANISATIE, ENZ...
- Registered office03/02/2022MAATSCHAPPELIJKE ZETEL
- Registered office17/08/2018MAATSCHAPPELIJKE ZETEL
- Mandates16/02/2015MAATSCHAPPELIJKE ZETEL - ONTSLAGEN - BENOEMINGEN
- Other06/11/2014RUBRIEK OPRICHTING (NIEUWE RECHTSPERSOON, OPENING BIJKANTOOR, ENZ...)
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2024Annual accounts 202412,4 k €↑
- 2023Annual accounts 20234 k €↓
- 2023Name changeDr. Bert Bravenboer, inwendige geneesk.
- 2022Annual accounts 202213,6 k €↓
- 2021Annual accounts 202165,3 k €↑
- 2021Name changeDr. Bert Bravenboer, inwendige geneeskunde
- 2020Annual accounts 202052,3 k €↓
- 2019Annual accounts 201964,4 k €↑
- 2018Annual accounts 201849,7 k €↑
- 2017Annual accounts 201728,3 k €↓
- 2015Annual accounts 201578,3 k €